XRP is currently trading at $1.86, consolidating near a key support zone while momentum remains weak. Institutional inflows into XRP-ETFs remain positive. Flow–XRP is currently trading at $1.86, consolidating near a key support zone while momentum remains weak. Institutional inflows into XRP-ETFs remain positive. Flow–

XRP ETF Inflows Hit $8.54M as Institutional Exposure Rises to $1.16B

2025/12/18 09:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • XRP is currently trading at $1.86, consolidating near a key support zone while momentum remains weak.
  • Institutional inflows into XRP-ETFs remain positive.
  • Flow–price divergence suggests accumulation rather than aggressive distribution.

With a significant amount of interest from Institutions, XRP has been tracking well as the digital market continues to evolve, despite the recent decrease in the value of the coin.

Interest from the investment community still appears to be focused on the flow data as well as the broader structure of the overall market. At press time, the coin is trading at $1.86 with a decrease of 2.99% over the past 24 hours.

ETF Flow Update Highlights Institutional Interest

As per the recent Update on X by XRPUdate, XRP ETPs have attracted a lot of capital from Institutional Investors, with XRP-related exchange-traded products showing $8.54 million in net inflows, increasing the total amount of ETF/ETP held assets to about $1.16 billion.

The trend of continuing net inflows into these ETPs is indicative of Institutional Investors responding positively to the coin and shows that even as the broader market continues to be uncertain, Institutions are continuing to engage with the coin.

Also Read: Price Near $2.10 as Breakout Could Open Path to $2.75

Chart Says As the Key Support Under Pressure


According to the daily TradingView chart, the coin’s trading activity appears to have settled into a support area between $1.85 – $1.90. The Relative Strength Index (RSI) remains below neutral, indicating an overall lack of momentum, and the declining On-Balance Volume (OBV) appears to show an overall lack of buying pressure on the coin. This current technical situation signals that the coin appears to be in consolidation and is not in the process of turning around anytime soon.

Source: TradingView

Coinglass Data Shows Flow–Price Divergence

According to Coinglass’s records of XRP exchange-traded product net inflows, many of the spikes of positive net inflows occurred during the month of November and into early December. The spikes of positive inflows coincided with the coin’s decline in price and demonstrate a divergence that is often associated with Institutions acquiring it during corrective price declines.

Source: Coinglass

In conclusion, XRP’s price movement is currently under pressure, and the steady stream of deposits into ETPs continues to build a case for the bullish view of XRP.

Once the coin stabilizes and holds above important support areas and an increase in the number of positive momentum indicators, it should be in a good place to make a stronger, directional price move upward when macroeconomic conditions improve.

Also Read: Holds 200 EMA As Short-Term Pullback Signals Next Potential Move

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3665
$1.3665$1.3665
+0.73%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09